Radiation therapy for renal transplant rejection refractory to pulse steroids and OKT3

被引:10
|
作者
Noyes, WR
Rodriguez, R
Knechtle, SJ
Pirsch, JD
Sollinger, HW
DAlessandro, AM
Chappell, R
Belzer, FO
Kinsella, TJ
机构
[1] UNIV WISCONSIN,SCH MED,DEPT HUMAN ONCOL,MADISON,WI 53792
[2] UNIV WISCONSIN,SCH MED,DEPT SURG,MADISON,WI 53792
[3] UNIV WISCONSIN,SCH MED,DEPT BIOSTAT,MADISON,WI 53792
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1996年 / 34卷 / 05期
关键词
renal transplant rejection; steroids and OKT3; radiation therapy;
D O I
10.1016/0360-3016(95)02159-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the response rate and kidney graft survival following local irradiation to the transplanted renal graft undergoing persistent rejection after medical management including pulse steroids and OKT3. The role of radiation for renal transplant rejection after failure of OKT3 has not been previously reported. Methods and Materials: From July 1, 1988 to July 1, 1994, 72 consecutive patients with kidney graft rejection were treated with local irradiation to the transplanted renal graft following failure of medical management. All patients received pulse steroids and OKT3, an anti-CD3 immunosuppressant. Patients who failed to respond to methylprednisolone and OKT3 therapy were referred for radiation therapy. The median time from the diagnosis of rejection to irradiation was 8 days. All kidney grafts received local graft irradiation to a total of 8 Gy delivered in four daily fractions. Results: Sixty (83%) patients initially responded to radiotherapy at 7 days after completion of radiotherapy, as defined by a decrease in serum creatinine. Thirty-five responding patients have not experienced a second episode of graft rejection. Overall, 43 (60%) patients have renal graft survival, with a median follow-up of 16 months (range of 6-73 months). Conclusion: It is concluded that there is a subgroup of kidney graft patients undergoing graft rejection who are refractory to pulse steroids and OKT3 therapy where irradiation may be an effective modality with high rates of response and a moderate rate of graft survival. However, a prospective, randomized trial in these medically refractory patients is needed to ascertain whether these results are clinically significant.
引用
收藏
页码:1055 / 1059
页数:5
相关论文
共 7 条
  • [1] Outcome of radiation therapy for renal transplant rejection refractory to chemical immunosuppression
    Nuyttens, JJ
    Harper, J
    Jenrette, JM
    Turrisi, AT
    RADIOTHERAPY AND ONCOLOGY, 2005, 74 (01) : 17 - 19
  • [2] Radiotherapy for rejection of renal transplant allografts refractory to medical immunosuppression
    Wahl, Andrew O.
    Small, William, Jr.
    Dixler, Irma
    Strom, Shayna
    Rademaker, Alfred
    Leventhal, Joseph
    Abecassis, Michael M.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (06): : 551 - 554
  • [3] PILOT EVALUATION OF 15-DEOXYSPERGUALIN FOR REFRACTORY ACUTE RENAL-TRANSPLANT REJECTION
    MATAS, AJ
    GORES, PF
    KELLY, SL
    BIELEFIELDSKROKOV, M
    KINASZCZUK, M
    GRUESSNER, RWG
    NAJARIAN, JS
    CLINICAL TRANSPLANTATION, 1994, 8 (02) : 116 - 119
  • [4] New scoring system identifies kidney outcome with radiation therapy in acute renal allograft rejection
    Chen, LM
    Godinez, J
    Thisted, RA
    Woodle, ES
    Thistlewaite, JR
    Powers, C
    Haraf, D
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (04): : 999 - 1003
  • [5] Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial
    Daw, Stephen
    Claviez, Alexander
    Kurch, Lars
    Stoevesandt, Dietrich
    Attarbaschi, Andishe
    Balwierz, Walentyna
    Beishuizen, Auke
    Cepelova, Michaela
    Ceppi, Francesco
    Fernandez-Teijeiro, Ana
    Fossa, Alexander
    Georgi, Thomas W.
    Hjalgrim, Lisa Lyngsie
    Hraskova, Andrea
    Leblanc, Thierry
    Mascarin, Maurizio
    Pears, Jane
    Landman-Parker, Judith
    Prelog, Tomaz
    Klapper, Wolfram
    Ramsay, Alan
    Kluge, Regine
    Dieckmann, Karin
    Pelz, Tanja
    Vordermark, Dirk
    Koerholz, Dieter
    Hasenclever, Dirk
    Mauz-Koerholz, Christine
    JAMA ONCOLOGY, 2025, : 258 - 267
  • [6] Novel use of adjuvant proton beam therapy in patient with pelvic renal transplant diagnosed with stage IB3 cervical adenocarcinoma
    Vasques, Pedro Versuti Del Cioppo
    Bakkum-Gamez, Jamie N.
    Dean, Patrick G.
    Molligan, Jeremy F.
    Garda, Allison E.
    GYNECOLOGIC ONCOLOGY REPORTS, 2024, 56
  • [7] Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients
    Schoenfelder, Kristina
    Moehlendick, Birte
    Eisenberger, Ute
    Kribben, Andreas
    Siffert, Winfried
    Heinemann, Falko M.
    Gaeckler, Anja
    Wilde, Benjamin
    Friebus-Kardash, Justa
    DIAGNOSTICS, 2024, 14 (19)